Pooled Safety Results through 1 Year of 2 Phase III Trials of Guselkumab in Patients with Psoriatic Arthritis

Proton Rahman; Christopher T. Ritchlin; Philip S. Helliwell; Wolf Henning Boehncke; Philip J. Mease; Alice B. Gottlieb; Shelly Kafka; Alexa P. Kollmeier; Elizabeth C. Hsia; Xie L. Xu; May Shawi; Shihong Sheng; Prasheen Agarwal; Bei Zhou; Paraneedharan Ramachandran; Yanli Zhuang; Iain B. McInnes

doi:10.3899/jrheum.201532

Pooled Safety Results through 1 Year of 2 Phase III Trials of Guselkumab in Patients with Psoriatic Arthritis

Proton Rahman, Christopher T. Ritchlin, Philip S. Helliwell, Wolf Henning Boehncke, Philip J. Mease, Alice B. Gottlieb, Shelly Kafka, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, May Shawi, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Paraneedharan Ramachandran, Yanli Zhuang, Iain B. McInnes

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Evaluate the safety of guselkumab (monoclonal antibody targeting interleukin [IL]-23p19) in patients with psoriatic arthritis (PsA) through 1 year (1Y) of the phase III DISCOVER-1 and DISCOVER-2 trials.

Original language	English
Pages (from-to)	1815-1823
Number of pages	9
Journal	Journal of Rheumatology
Volume	48
Issue number	12
DOIs	https://doi.org/10.3899/jrheum.201532
State	Published - 1 Dec 2021

Keywords

Adverse effects
Biologics
Psoriatic arthritis
Safety
Tolerability

Access to Document

10.3899/jrheum.201532

Cite this

Rahman, P., Ritchlin, C. T., Helliwell, P. S., Boehncke, W. H., Mease, P. J., Gottlieb, A. B., Kafka, S., Kollmeier, A. P., Hsia, E. C., Xu, X. L., Shawi, M., Sheng, S., Agarwal, P., Zhou, B., Ramachandran, P., Zhuang, Y., & McInnes, I. B. (2021). Pooled Safety Results through 1 Year of 2 Phase III Trials of Guselkumab in Patients with Psoriatic Arthritis. Journal of Rheumatology, 48(12), 1815-1823. https://doi.org/10.3899/jrheum.201532

@article{a809cda8c84f4c3dbe7972e3068b8f04,

title = "Pooled Safety Results through 1 Year of 2 Phase III Trials of Guselkumab in Patients with Psoriatic Arthritis",

abstract = "Evaluate the safety of guselkumab (monoclonal antibody targeting interleukin [IL]-23p19) in patients with psoriatic arthritis (PsA) through 1 year (1Y) of the phase III DISCOVER-1 and DISCOVER-2 trials.",

keywords = "Adverse effects, Biologics, Psoriatic arthritis, Safety, Tolerability",

author = "Proton Rahman and Ritchlin, {Christopher T.} and Helliwell, {Philip S.} and Boehncke, {Wolf Henning} and Mease, {Philip J.} and Gottlieb, {Alice B.} and Shelly Kafka and Kollmeier, {Alexa P.} and Hsia, {Elizabeth C.} and Xu, {Xie L.} and May Shawi and Shihong Sheng and Prasheen Agarwal and Bei Zhou and Paraneedharan Ramachandran and Yanli Zhuang and McInnes, {Iain B.}",

year = "2021",

month = dec,

day = "1",

doi = "10.3899/jrheum.201532",

language = "English",

volume = "48",

pages = "1815--1823",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "12",

}

Rahman, P, Ritchlin, CT, Helliwell, PS, Boehncke, WH, Mease, PJ, Gottlieb, AB, Kafka, S, Kollmeier, AP, Hsia, EC, Xu, XL, Shawi, M, Sheng, S, Agarwal, P, Zhou, B, Ramachandran, P, Zhuang, Y & McInnes, IB 2021, 'Pooled Safety Results through 1 Year of 2 Phase III Trials of Guselkumab in Patients with Psoriatic Arthritis', Journal of Rheumatology, vol. 48, no. 12, pp. 1815-1823. https://doi.org/10.3899/jrheum.201532

TY - JOUR

T1 - Pooled Safety Results through 1 Year of 2 Phase III Trials of Guselkumab in Patients with Psoriatic Arthritis

AU - Rahman, Proton

AU - Ritchlin, Christopher T.

AU - Helliwell, Philip S.

AU - Boehncke, Wolf Henning

AU - Mease, Philip J.

AU - Gottlieb, Alice B.

AU - Kafka, Shelly

AU - Kollmeier, Alexa P.

AU - Hsia, Elizabeth C.

AU - Xu, Xie L.

AU - Shawi, May

AU - Sheng, Shihong

AU - Agarwal, Prasheen

AU - Zhou, Bei

AU - Ramachandran, Paraneedharan

AU - Zhuang, Yanli

AU - McInnes, Iain B.

PY - 2021/12/1

Y1 - 2021/12/1

N2 - Evaluate the safety of guselkumab (monoclonal antibody targeting interleukin [IL]-23p19) in patients with psoriatic arthritis (PsA) through 1 year (1Y) of the phase III DISCOVER-1 and DISCOVER-2 trials.

AB - Evaluate the safety of guselkumab (monoclonal antibody targeting interleukin [IL]-23p19) in patients with psoriatic arthritis (PsA) through 1 year (1Y) of the phase III DISCOVER-1 and DISCOVER-2 trials.

KW - Adverse effects

KW - Biologics

KW - Psoriatic arthritis

KW - Safety

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=85120452303&partnerID=8YFLogxK

U2 - 10.3899/jrheum.201532

DO - 10.3899/jrheum.201532

M3 - Article

C2 - 33934076

AN - SCOPUS:85120452303

SN - 0315-162X

VL - 48

SP - 1815

EP - 1823

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 12

ER -

Pooled Safety Results through 1 Year of 2 Phase III Trials of Guselkumab in Patients with Psoriatic Arthritis

Abstract

Keywords

Access to Document

Fingerprint

Cite this